Table 2.

Clinical and histopathological data related to prognostic groups in 58 patients with M0¹

Variables	N0-NPNL	N1a-NPNL	N1b-NPNL2	p value
Patients,n (%)	37 (63)	9 (16)	12 (20)
Gender,n (%)
Female	24 (65)	5 (56)	6 (50)	0.625
Male	13 (35)	4 (44)	6 (50)
Age at thyroid surgery, years
Median [range]	53 [6–80]	59 [29–77]	62.5 [13–82]	0.218
Preoperative serum calcitonin
Median [range], pmol/L	146 [1.1–2,450]	554 [4.0-2,100]	1,355 [271–8,630]	<0.001
Patients,n (%)
≤20 pmol/L	10 (27)	2 (22)	0
21–500 pmol/L	20 (54)	2 (22)	2 (16.5)
501–1,000 pmol/L	3 (8)	4 (34)	2 (16.5)	0.001
1,001–3,000 pmol/L	4 (11)	2 (22)	5 (42)
>3,000 pmol/L	0	0	3 (25)
Tumor diameter, mm
Median [range]	17 [1–45]	23 [6–58]	27.5 [8–80]	0.002
Patients,n (%)
≤20 mm	28 (76)	4 (44)	3 (25)	0.004
>20 mm	9 (34)	5 (56)	9 (75)
Extrathyroidal extension, n (%)
Not present	35 (97)	9 (100)	3 (25)	<0.001
Present	1 (3)	0	9 (75)
Available data (n =57)	36	9	12
Number of metastatic lymph nodes
Median [range]	0	1 [1–6]	12 [3–33]	<0.001
Biochemical cure3, n (%)	35 (95)	6 (67)	2 (17)	<0.001
Available data (n =57)	36	9	12

Univariate analysis. NPNL, no clinical progression to next tumor level.

¹Patients with Mx or M1 at primary surgery or progression to the next clinical tumor level were excluded.

²Ipsi- and contralateral pN1b in 1 patient and ipsilateral pN1b in 11 patients.

³After completed primary surgery.